Portal Hypertension and Primary Biliary Cirrhosis: Effect of Long-Term Ursodeoxycholic Acid Treatment

Gastroenterology

Volumn 135, Issue 5, 2008, Pages 1552-1560

  Huet, Pierre Michel ^a,b   Vincent, Catherine ^a   Deslaurier, Julie ^a   Coté, Jean ^a   Matsutami, Shoichi ^a   Boileau, Robert ^a   Huet van Kerckvoorde, Jacline ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL; TREATMENT RESPONSE;

EID: 55249105177     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.07.019     Document Type: Article

References (33)

1. Xu B., Broome U., Uzunel M., et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol 163 (2003) 1275-1298
2. Zeegen R., Stansfeld A.G., Dawson A.M., et al. Bleeding oesophageal varices as the presenting feature in primary biliary cirrhosis. Lancet 2 (1969) 9-13
3. Lebrec D., Sicot C., Degott C., et al. Portal hypertension and primary biliary cirrhosis. Digestion 14 (1976) 220-226
4. Boyer T., Triger D.R., Horisawa M., et al. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology 72 (1977) 584-589
5. Pomier-Layrargues G., Kusielewiicz D., Willems B., et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology 5 (1985) 415-418
6. Kew M.C., Varma R.R., Dos Santos H.A., et al. Portal hypertension in primary biliary cirrhosis. Gut 12 (1971) 830-834
7. Navasa M., Parés A., Bruguera M., et al. Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol 5 (1987) 292-298
8. Gores G., Wiesner R.H., Dickson E.R., et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 96 (1989) 1552-1559
9. Poupon R., Chrétien Y., Poupon R.E., et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1 (1987) 834-836
10. Heathcote E.J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31 (2000) 1005-1013
11. Poupon R.E., Balkau B., Escwège E., et al., UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 324 (1991) 1548-1554
12. Lindor K.D., Dickson E.R., Baldus W.P., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106 (1994) 1284-1290
13. Heathcote E.J., Cauch-Dudek K., Walker V., et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19 (1994) 1149-1156
14. Combes B., Carithers Jr. R.L., Maddrey W.C., et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22 (1995) 759-766
15. Poupon R.E., Lindor K.D., Cauch-Dudek K., et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113 (1997) 884-890
16. Goulis J., Leandro G., and Burroughs A.K. Randomized controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (1999) 1053-1060
17. Lindor K.D., Jorgensen R.A., Therneau T.M., et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 72 (1997) 1137-1140
18. Combes B., Luketic V.A., Peters M., et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 99 (2004) 264-268
19. Ludwig J., Dickson E.R., and McDonald G.S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379 (1978) 103-112
20. Coperchot C., Carrat F., Bonnand A.M., et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32 (2000) 1196-1199
21. Murray K.F., and Carithers Jr. R.L. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 41 (2005) 1407-1432
22. Grambsch P.M., Dickson E.R., Kaplan M., et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model established its generalizability. Hepatology 10 (1989) 846-850
23. Abraldes J.G., Tarantino I., Turnes J., et al. Hemodynamic response to pharmacological treatment of portal hypertension and long term prognosis of cirrhosis. Hepatology 37 (2003) 902-908
24. Parés A., Caballeria L., and Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130 (2006) 715-720
25. Van Hoogstraten H.J.F., Hansen B.E., van Buuren H.R., et al., Dutch Multi-Centre PBC Study Group. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. J Hepatol 31 (1999) 256-262
26. Leuschner M., Dietrich C.F., You T., et al. Characterisation of patients with primary biliary cirrhosis responding to long-term ursodeoxycholic acid treatment. Gut 46 (2000) 121-126
27. Jorgensen R., Angulo P., Dickson E.R., et al. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol 97 (2002) 2647-2650
28. Chan C.W., Gunsar F., Feudjo M., et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 21 (2005) 217-226
29. Coperchot C., Poujol-Robert A., Wendum D., et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary cirrhosis. Liver Int 24 (2004) 187-193
30. Miyake Y., Iwasaki Y., Terada R., et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43 (2005) 951-957
31. Coperchot C., Carrat F., Dahr A., et al. The effect of ursodeoxycholic acid on the natural course of primary biliary cirrhosis. Gastroenterology 128 (2005) 297-303
32. Ter Borg P.C.J., Schalm S., Hansen B.E., et al., Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101 (2006) 2044-2050
33. Castera L., Forns X., and Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008) 835-847